What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?

Journal of Clinical Medicine Research
doi 10.14740/jocmr3004w
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elmer Press, Inc.

Related search

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2017English

Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Effects of Sodium Glucose Cotransporter Type 2 Inhibitors on Heart Failure

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2019English

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2015English

Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2019English

Differential Cardiovascular Profiles of Sodium-Glucose Cotransporter 2 Inhibitors: Critical Evaluation of Empagliflozin

Therapeutics and Clinical Risk Management
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy